**Core tip:** Upper gastrointestinal bleeding (UGIB) after an acute myocardial infarction (AMI) is not an uncommon complication. Acute UGIB caused by Mallory-Weiss syndrome (MWS) after an AMI has not been previously reported. Here we report the diagnosis and management of a 57-year-old AMI patient who developed UGIB caused by MWS shortly after the primary coronary intervention. In addition to blood transfusion and acid inhibition treatment, early endoscopy was employed, and MWS was diagnosed. Bleeding was stopped by endoscopic hemoclip intervention with close monitoring of the hemodynamic status.

INTRODUCTION
============

Acute myocardial infarction (AMI) is related to an increased incidence (8.9%) of upper gastrointestinal bleeding (UGIB)\[[@B1]\]. The addition of this comorbidity raises in-hospital and long-term mortality to 25%-35%\[[@B1]-[@B3]\]. However, due to a paucity of studies on this topic and the need for interdisciplinary collaboration, patients may not receive proper management.

A bleeding complication after a coronary intervention is a dilemma for doctors. Continuing platelet inhibition therapy increases the risk of hemorrhagic shock, while interruption of antiplatelet treatment increases the risk of stent thrombosis. Both considerations should be carefully balanced after reviewing individual facts and the guidelines. In addition, acute UGIB and AMI can both cause hemodynamic instability and increase mortality\[[@B4],[@B5]\].

Mallory-Weiss syndrome (MWS) is a rare disease that can cause severe UGIB due to esophageal and cardial mucosal tears\[[@B6]\]. Here, we report the treatment of a 57-year-old ST elevation myocardial infarction (STEMI) patient who suffered an acute UGIB caused by MWS shortly after a primary coronary intervention (PCI).

CASE PRESENTATION
=================

Chief complaints
----------------

A 57-year-old male patient was admitted to China-Japan Union Hospital of Jilin University (Changchun, Jilin, China) for acute persistent chest pain for 5 h after drinking.

History of present illness
--------------------------

The patient's symptoms started 5 h ago when he was drinking, and only alleviated a little when he was referred to the hospital.

History of past illness
-----------------------

His past medical history, including a coronary artery bypass grafting history, described a vein graft to the left anterior descending artery (LAD) 3 years ago. The patient had no history of hypertension, diabetes, alcohol abuse, liver cirrhosis, or gastrointestinal diseases, but had a 25-pack-year smoking history.

Personal and family history
---------------------------

The patient had no family cardiovascular diseases.

Physical examination upon admission
-----------------------------------

Physical examination showed bradycardia (heart rate: 50 bpm) and hypotension (blood pressure: 90/60 mmHg) but no other abnormalities.

Laboratory examinations
-----------------------

Laboratory assessments showed a normal red blood cell (RBC) count, normal hemoglobin level (133 g/L), and normal coagulation test results. Cardiac biomarkers were significantly increased (TnI 2.40 ng/mL, myoglobin 300 mg/L, and CK-MB 32.6 U/L).

Imaging examinations
--------------------

Electrocardiography **(**ECG) showed ST elevations in the inferior wall leads (Figure [1A](#F1){ref-type="fig"}). Emergency coronary angiography (CAG) showed a distal right coronary artery (RCA) occlusion and a thrombus (TIMI thrombus grade 5) (Figure [2C](#F2){ref-type="fig"}). There was a 40%-50% \[quantitative coronary analysis (QCA)\] moderate stenosis of the distal left main artery. Native LAD was occluded, and there was a 90% (QCA) severe stenosis in the distal circumflex artery (Figure [2B](#F2){ref-type="fig"}). The saphenous vein graft to LAD was normal (Figure [2A](#F2){ref-type="fig"}). After intervention, chest pain was relieved, and ECG (Figure [1B](#F1){ref-type="fig"}) showed that the elevated ST segment returned to normal but with a T wave inversion.

![Electrocardiography examinations. A: Electrocardiography (ECG) on admission; B: ECG after intervention; C: ECG when the patient had the symptoms of vomit, nausea, and chest pain.](WJCC-7-4407-g001){#F1}

![Coronary and esophageal diseases of the patient and subsequent treatments. A: Occluded left anterior descending artery (LAD) and saphenous vein graft to the LAD; B: Native left coronary of the patient. The dash line indicates the track of the occluded LAD; C: Acute occlusion of the right coronary artery (RCA); D: Post-stenting RCA; E and F: Representative superficial mucosal tear (arrow) due to Mallory-Weiss syndrome; G and H: Hemoclip treatment of the tear and confirmation of no active bleeding. SVG: Saphenous vein graft; LAD: Left anterior descending artery; RCA: Right coronary artery; MWS: Mallory-Weiss syndrome.](WJCC-7-4407-g002){#F2}

The patient experienced nausea and vomiting and subxiphoid chest pain 6 h after the procedure. The vomitus originally included the stomach contents without blood. ECG was rechecked to rule out acute thrombus formation, but no obvious changes were observed (Figure [1C](#F1){ref-type="fig"}). Twenty minutes later, the patient vomited again, and this time the vomitus was bloody (approximately 400 mL). Although optimal medical treatment was given, no obvious improvement was seen. An esopha-gogastroduodenoscopy (EGD) was performed 7 hours after the PCI. A 2.0 cm, actively bleeding mucosal tear was found in the cardia. No ulcer in the stomach or duodenum and no esophageal varices or mucosal erosion was observed (Figure [2E](#F2){ref-type="fig"}, [2F](#F2){ref-type="fig"}).

FINAL DIAGNOSIS
===============

According to the symptoms, ECG findings, cardiac biomarkers, CAG findings, EGD findings, and the whole course of the disease, the patient was diagnosed with acute inferior wall STEMI, MWS, and acute UGIB.

TREATMENT
=========

After emergency CAG, primary percutaneous coronary intervention was performed. The RCA was recanalized after thrombus aspiration, and a 3.5 mm × 33 mm drug eluting stent (Firebird2, Microport, China) was implanted in the distal RCA (Figure [2D](#F2){ref-type="fig"}).

The patient was first given antiemetics (metoclopramide, 10 mg, i.m.) when he had the symptoms of vomit and nausea, but the symptoms were not relieved.

After the patient had bloody vomitus, all antithrombotic drugs were stopped and food and water were strictly restricted. A proton pump inhibitor (PPI, pantoprazole, 40 mg, i.v.) and somatostatin (250 mg, q8h, i.v.) were intravenously administered. The patient vomited again 15 min later, and this time, the vomitus contained 300 mL of blood. Three units of RBC suspension was immediately perfused.

At the same time, an early endoscopic examination with close monitoring of the hemodynamic status was recommended. After the diagnosis of MWS by EGD, hemoclip treatment with seven small titanium clips \[endoclips (HX610090L), OLYMPUS, JP\] was performed, and the bleeding was stopped (Figure [2G](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}). The wound was repeatedly washed, and no active bleeding was observed.

After the treatment, the chest pain was relieved and no further hematemesis occurred. Blood pressure returned to normal. To prevent stent thrombosis, dual antiplatelet therapy (aspirin 100 mg/d and clopidogrel 75 mg/d) was restarted.

OUTCOME AND FOLLOW-UP
=====================

Ten days later, the patient was discharged from the hospital. Laboratory assessments showed a normal RBC count and hemoglobin level.

DISCUSSION
==========

We describe the process of diagnosis and salvage treatment for a case of MWS-induced acute UGIB after an AMI intervention. When there is acute UGIB after an AMI, the in-hospital and long-term mortality of the patient can substantially increase to 25.9% and 34.1%, respectively\[[@B1]\]. Hematemesis can cause a management dilemma for clinicians who need to balance the discontinuation of antithrombotic drugs to prevent bleeding and possible acute thrombosis of the stent.

UGIB after AMI or primary PCI is usually caused by stress\[[@B7]\]. MWS, also called cardial mucosal tear syndrome, is characterized by massive hematemesis, severe vomiting, and longitudinal tears of the esophagogastric junction. MWS is not a common cause of UGIB after AMI. As this case showed, hematemesis often starts with severe vomiting and massive bright red blood loss. When no improvement is seen after routine inhibition of gastric acid secretion and other drugs, early EGD can help provide a clear diagnosis indicating that MWS caused UGIB.

Although the mechanism is not fully understood, it is generally believed that the stomach contents enter the esophagus due to vomiting and the diaphragm contraction causes the pressure in the distal esophagus to instantly increase, leading to a mucosal tear of the cardia\[[@B8]\].

MWS-caused acute UGIB is high risk because massive blood loss induces hemodynamic instability. When MWS occurs after an AMI, it results in further hemodynamic instability and has potential for life-threating ventricular arrhythmias. Besides, intensified antithrombotic treatment of dual antiplatelet combined with anticoagulation drugs was commonly adopted in AMI post-PCI management, which definitely would increase the difficulty of disease differential diagnosis and hemostasis treatment. The key management of MWS and AMI patients is an early endoscopic examination and hemoclip treatment\[[@B8]\]. This process requires close collaboration between cardiologists and endoscopy experts.

No consensus has been reached regarding liberal or restrictive transfusion therapy for acute coronary syndrome with acute blood loss, although in current clinical settings, patients whose Hb \< 8 g/dL with ischemic symptoms or Hb \< 7 g/dL without symptoms would be recommend to receive packed RBC transfusion\[[@B9]\]. The on-going large clinical trial (MINT trial)\[[@B10]\] can possibly answer this question. The transfusion in this case was based on the fact that there was acute large-volume blood loss and it was not known whether there would be further bleeding.

Post-endoscopy management should include the prevention of recurrent bleeding. As recommended by the guidelines\[[@B11],[@B12]\], administration of a prophylactic PPI is protective for most UGIB, including MWS after a coronary intervention, with dual antiplatelet therapy\[[@B13]\]. Dual antiplatelet therapy can be continued with the assurance of no active bleeding under endoscopy.

AMI patients often have gastrointestinal symptoms, such as nausea and vomiting (55%)\[[@B14]\], early in the event, and nausea or vomiting can be the predisposing factor for MWS. Therefore, in patients with AMI combined with UGIB, clinicians should be vigilant for the possibility of MWS. In terms of treatment, in addition to the optimal medication, it is necessary to perform an early EGD to determine the cause of bleeding and, if necessary, stop bleeding with hemoclip therapy and other necessary interventions.

CONCLUSION
==========

MWS can lead to severe UGIB after AMI and is associated with accompanying symptoms, such as nausea and vomiting. An early EGD should be performed on such patients to distinguish between stress-induced and antithrombotic drug-induced bleeding and to determine what treatment is needed to stop the bleeding.
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